Dacia Oakeson, NP
Psychiatric/Mental Health · Hastings, NENPI 1013271246
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,850 of the $31,814 with a category attached, or 84.4%. AbbVie accounts for 95.5% of it on its own, with 26 other manufacturers making up the rest. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $116.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Otsuka America Pharmaceutical, Inc.$323
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$123
- Lilly USA, LLC$111
- Novo Nordisk$107
- Pfizer$82
- plus $697 from 21 others
What the payments were for
- Speaking & faculty fees$26,85084%
- Travel & lodging$1,2784%
- Food & beverage$3,68612%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 192 | $30,371 |
| Otsuka America Pharmaceutical, Inc. | 15 | $323 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $123 |
| Lilly USA, LLC | 8 | $111 |
| Novo Nordisk | 7 | $107 |
| Pfizer | 5 | $82 |
| Neurocrine Biosciences, Inc. | 1 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| Bayer | 4 | $58 |
| Exact Sciences | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Axsome Therapeutics, Inc. | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Merck | 3 | $41 |
| Johnson & Johnson | 2 | $35 |
| Abiomed | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Amgen | 2 | $26 |
| Organon | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Corium, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Alkermes, Inc. | 1 | $13 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$27,783
How this compares
$31,814 in reported general payments places this provider in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 71 | $102,491 |
| OzempicSemaglutide | 83 | $83,692 |
| MounjaroTirzepatide | 29 | $35,985 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $30,153 |
| FarxigaDapagliflozin Propanediol | 23 | $28,465 |
| EliquisApixaban | 21 | $22,867 |
| TrulicityDulaglutide | 20 | $22,455 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,089 |
| RexultiBrexpiprazole | 12 | $18,597 |
| LinzessLinaclotide | 28 | $17,824 |
| FetzimaLevomilnacipran Hcl | 13 | $14,780 |
| XareltoRivaroxaban | 28 | $14,386 |
| Emgality PenGalcanezumab-Gnlm | 18 | $13,221 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,561 |
| TrintellixVortioxetine Hydrobromide | 17 | $10,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess, Fetzima | $30,371 | $135,094112 claims |
| Novo NordiskOzempic | $107 | $83,69283 claims |
| Lilly USA, LLCMounjaro, Trulicity | $111 | $58,44049 claims |
| PfizerEliquis, Nurtec Odt | $82 | $44,95632 claims |
| GSKTrelegy Ellipta | $11 | $30,15333 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $323 | $18,59712 claims |
| Johnson & JohnsonXarelto | $35 | $14,38628 claims |
| Axsome Therapeutics, Inc.Auvelity | $46 | $12,56112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $47 | $10,93917 claims |
| MerckBelsomra | $41 | $5,68112 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $5,29822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Hastings
- Suzanne GreggHastings$11K
- Erica FerrellHastings$6K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Helen TrotterLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.